Possibilities for prediction and prevention of preeclampsia in women with diabetes mellitus

Cover Page


Based on the analysis of literature data, the role and serum levels of the main angiogenic (placental growth factor (PlGF)) and antiangiogenic vascular factors (endoglin (sENG), soluble fms-like type 1 tyrosine kinase (sFlt-1)) have been assessed in pregnant women with different types of diabetes mellitus (DM) in both the plasma and placenta. We evaluated the effectiveness of administration of low doses of acetylsalicylic acid for preventing preeclampsia in diabetic pregnancy. In addition, the effectiveness of using the sFlt-1/PlGF and PlGF/sENG ratios as possible test systems for prediction of the complication in this patient population was evaluated. It has been found that the synthesis of the studied biomarkers fails in the diabetic pregnancy, with the expression levels of sENG and sFlt-1 increased and PlGF reduced. However, the insufficient research does not allow us to make unambiguous conclusions about the practical validity of the evaluation of the plasma content of these vascular factors and their ratios for the preeclampsia prediction in pregnant women with DM. The presented data on acetylsalicylic acid administration to these women are also controversial. Given the high incidence of adverse perinatal outcomes associated with DM during pregnancy, an additional assessment of the prognostic risk model for the development of preeclampsia and the appropriateness of aspirin administration is needed. Therefore, further randomized studies are required to address this issue.

Roman V. Kapustin

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott

Author for correspondence.
Email: kapustin.roman@gmail.com

Russian Federation, Saint Petersburg


  1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631-44. doi: 10.1016/S0140-6736(10)60279-6.
  2. Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic pregnancies: A large, population-based study. Diabetes Care. 2009;32(11):2005-9. doi: 10.2337/dc09-0656.
  3. Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia. Current understanding of its pathophysiology. Nat Rev Nephrol. 2014;10(8):466-80. doi: 10.1038/nrneph.2014.102.
  4. Holmes VA, Young IS, Patterson CC, et al.; Diabetes and Pre-eclampsia Intervention Trial Study Group. Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial. Diabetes Care. 2011;34(8):1683-8. doi: 10.2337/dc11-0244.
  5. Hanson U, Persson B. Epidemiology of pregnancy-induced hypertension and pre-eclampsia in type 1 (insulin-dependent) diabetic pregnancies in Sweden. Acta Obstet Gynecol Scand. 1998;77(6):620-4.
  6. Bar J, Chen R, Schoenfeld A. Pregnancy outcome in patients with insulin dependent diabetes mellitus and diabetic nephropathy treated with ACE inhibitors before pregnancy. J Pediatr Endocrinol Metab. 1999;12:659-65.
  7. Ekbom P. Pre-pregnancy microalbuminuria predicts preeclampsia in insulin-dependent diabetes mellitus. Copenhagen Preeclampsia in Diabetic Pregnancy Study Group. Lancet. 1999;353:377.
  8. Piccoli GB, Clari R, Ghiotto S, et al. Type 1 diabetes, diabetic nephropathy, and pregnancy: a systematic review and meta-study. Rev Diabet Stud. 2013;10(1):6-26. doi: 10.1900/RDS.2013.10.6.
  9. Greene MF, Hare JW, Krache M, et al. Prematurity among insulin-requiring diabetic gravid women. Am J Obstet Gynecol. 1989;161(1):106-11.
  10. Gordon M, Landon MB, Samuels P, et al. Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy. Obstet Gynecol. 1996;87(3):401-9.
  11. Reece EA, Wu YK, Zhao Z, Dhanasekaran D. Dietary vitamin and lipid therapy rescues aberrant signaling and apoptosis and prevents hyperglycemia-induced diabetic embryopathy in rats. Am J Obstet Gynecol. 2006;194:580-5. doi: 10.1016/j.ajog.2005.08.052.
  12. Miodovnik M, Rosenn BM, Khoury JC, et al. Does pregnancy increase the risk for development and progression of diabetic nephropathy? Am J Obstet Gynecol. 1996;174(4):1180-9.
  13. Kovilam O, Rosenn B, Miodovnik M, et al. Is proliferative retinopathy a risk factor for adverse pregnancy outcome in women with Type 1 diabetes? J Soc Gynecol Invest. 1997;4:(suppl 1)152A.
  14. Sibai BM, Caritis S, Hauth J, et al. Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol. 2000;182(2):364-9.
  15. Hauth JC, Clifton RG, Roberts JM, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal insulin resistance and preeclampsia. Am J Obstet Gynecol. 2011;204(4):327.e1-6. doi: 10.1016/j.ajog.2011.02.024.
  16. Капустин Р.В., Аржанова О.Н., Сельков С.А., Пакин В.С. Роль адипокинов в патогенезе перинатальных осложнений при нарушении углеводного обмена у матери // Молекулярная медицина. - 2017. - № 5. - С. 14-23. [Kapustin RV, Arzhanova ON, Selkov SA, Pakin VS. The role of adipokines in pathogenesis of perinatal complications in pregnant women with disorders of carbohydrate menabolism. Molecular medicine. 2017;(5):14-23. (In Russ.)]
  17. Suhonen L, Teramo K. Hypertension and pre-eclampsia in women with gestational glucose intolerance. Acta Obstet Gynecol Scand. 1993;72(4):269-72.
  18. Martinez AE, Gonzales OM, Quninones GA, et al. Hyperinsulinemia in glucose-tolerant women with pre-eclampsia: A controlled study. Am J Hypertens. 1996;9:610-4.
  19. Joffe GM, Esterlitz JR, Levine RJ, et al. The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Am J ObstetGynecol. 1998;179:1032-7.
  20. Bryson CL, Ioannou GN, Rulyak SJ, Critchlow C. Association between gestational diabetes and pregnancy-induced hypertension. Am J Epidemiol. 2003;158(12):1148-53.
  21. Langer O, Conway DL, Berkus MD, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343(16):1134-8. doi: 10.1056/NEJM200010193431601.
  22. Crowther CA, Hiller JE, Moss JR, et al.; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352(24):2477-86. doi: 10.1056/NEJMoa042973.
  23. HAPO Study Cooperative Research Group. Metzger BE, Lowe LP, Dyer AR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991-2002. doi: 10.1056/NEJMoa0707943.
  24. Schneider S, Freerksen N, Röhrig S, et al. Gestational diabetes and preeclampsia - similar risk factor profiles? Early Hum Dev. 2012;88(3):179-84. doi: 10.1016/j.earlhumdev.2011.08.004.
  25. Nerenberg KA, Johnson JA, Leung B, et al. Risks of gestational diabetes and preeclampsia over the last decade in a cohort of Alberta women. J Obstet Gynaecol Can. 2013;35(11):986-94. doi: 10.1016/S1701-2163(15)30786-6.
  26. Ostlund I, Haglund B, Hanson U. Gestational diabetes and preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2004;113(1):12-6.
  27. Yogev Y, Langer O. Pregnancy outcome in obese and morbidly obese gestational diabetic women. Eur J Obstet Gynecol Reprod Biol. 2008;137(1):21-6. doi: 10.1016/j.ejogrb.2007.03.022.
  28. Shand AW, Bell JC, McElduff A, et al. Outcomes of pregnancies in women with pre-gestational diabetes mellitus and gestational diabetes mellitus; a population-based study in New South Wales, Australia, 1998-2002. Diabet Med. 2008;25(6):708-15. doi: 10.1111/j.1464-5491.2008.02431.x.
  29. Stella CL, O’Brien JM, Forrester KJ, et al. The coexistence of gestational hypertension and diabetes: influence on pregnancy outcome. Am J Perinatol. 2008;25(6):325-9. doi: 10.1055/s-2008-1078758.
  30. Svare JA, Hansen BB. Perinatal complications in women with gestational diabetes mellitus. Acta Obstet Gynecol Scand. 2001;80:899-904.
  31. Rowan JA, Hague WM, Gao W, et al.; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003-15. doi: 10.1056/NEJMoa0707193.
  32. Jacobson GF, Ramos GA, Ching JY, et al. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol. 2005;193(1):118-24. doi: 10.1016/j.ajog.2005.03.018.
  33. Levine RJ, Lam C, Qian C, et al.; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992-1005. doi: 10.1056/NEJMoa055352.
  34. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642-9. doi: 10.1038/nm1429.
  35. Stepan H, Geide A, Faber R. Soluble fms-like tyrosine kinase 1. N Engl J Med. 2004;351:2241-2. doi: 10.1056/NEJM200411183512123.
  36. Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012 Jan;206(1):58.e1-8. doi: 10.1016/j.ajog.2011.07.037.
  37. Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med. 2014;27(2):132-44. doi: 10.3109/14767058.2013.806905.
  38. Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med. 2009;22(11):1021-38. doi: 10.3109/14767050902994754.
  39. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672-83. doi: 10.1056/NEJMoa031884.
  40. Cohen A, Lim KH, Lee Y, et al. Circulating levels of the antiangiogenic marker soluble FMS-like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes. Diabetes Care. 2007;30(2):375-7. doi: 10.2337/dc06-1514.
  41. Yu Y, Jenkins AJ, Nankervis AJ, et al. Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women. Diabetologia. 2009;52(1):160-8. doi: 10.1007/s00125-008-1182-x.
  42. Powers RW, Jeyabalan A, Clifton RG, et al.; Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One. 2010;5(10):e13263. doi: 10.1371/journal.pone.0013263.
  43. Holmes VA, Young IS, Patterson CC, et al.; Diabetes and Preeclampsia Intervention Trial (DAPIT) Study Group. The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes. Diabetes Care. 2013;36(11):3671-7. doi: 10.2337/dc13-0944.
  44. El-Tarhouny SA, Almasry SM, Elfayomy AK, et al. Placental growth factor and soluble Fms-like tyrosine kinase 1 in diabetic pregnancy: A possible relation to distal villous immaturity. Histol Histopathol. 2014;29(2):259-72. doi: 10.14670/HH-29.259.
  45. Lappas M. Markers of endothelial cell dysfunction are increased in human omental adipose tissue from women with pre-existing maternal obesity and gestational diabetes. Metabolism. 2014;63(6):860-73. doi: 10.1016/j.metabol.2014.03.007.
  46. Troncoso F, Acurio J, Herlitz K, et al. Gestational diabetes mellitus is associated with increased pro-migratory activation of vascular endothelial growth factor receptor 2 and reduced expression of vascular endothelial growth factor receptor 1. PLoS One. 2017;12(8):e0182509. doi: 10.1371/journal.pone.0182509.
  47. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21(1):9-23. doi: 10.1080/14767050701830480.
  48. Roberge S, Nicolaides KH, Demers S, et al. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 2013;41(5):491-9. doi: 10.1002/uog.12421.
  49. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116(2 Pt 1):402-14. doi: 10.1097/AOG.0b013e3181e9322a.
  50. Magee LA, Pels A, Helewa M, et al.; Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014;36(5):416-41.
  51. ACOG: Task Force on Hypertension in Pregnancy; Hypertension, Pregnancy-Induced-Practice Guideline, American College of Obstetrician and Gynecologist. Washington: Library of congress, 2013: WQ 244.
  52. Wójtowicz A, Undas A, Huras H, et al. Aspirin resistance may be associated with adverse pregnancy outcomes. Neuro Endocrinol Lett. 2011;32(3):334-9.
  53. Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(2):110-120.e6. doi: 10.1016/j.ajog.2016.09.076.
  54. Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2017;216(2):121-128.e2. doi: 10.1016/j.ajog.2016.10.016.
  55. LeFevre ML; U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(11):819-26. doi: 10.7326/M14-1884.
  56. WHO recommendations for prevention and treatment of preeclampsia and eclampsia. Geneva: World Health Organization; 2014. ISBN-13: 978-92-4-154833-5.
  57. Redman CW. Hypertension in pregnancy: the NICE guidelines. Heart. 2011;97(23):1967-9. doi: 10.1136/heartjnl-2011-300949.
  58. American College of Obstetricians and Gynecologists. Practice advisory on low-dose aspirin and prevention of preeclampsia: updated recommendations. 2016.
  59. Garner PR. Type 1 diabetes mellitus and pregnancy. Lancet. 1995;346:152-61.
  60. Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998;338(11):701-5. doi: 10.1056/NEJM199803123381101.


Abstract - 197

PDF (Russian) - 97


Copyright (c) 2018 Kapustin R.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.